Amedisys Income Statement Research

AMED Stock

USD 91.16 0.08 0.09%

Most accounts from Amedisys' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Amedisys current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Amedisys Valuation and Amedisys Correlation analysis.

For information on how to trade Amedisys Stock refer to our How to Trade Amedisys Stock guide.

At present, Amedisys' Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Total Revenue is expected to grow to about 2.3 B, whereas Gross Profit is forecasted to decline to about 447.4 M.

For information on how to trade Amedisys Stock refer to our How to Trade Amedisys Stock guide.At present, Amedisys' Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Total Revenue is expected to grow to about 2.3 B, whereas Gross Profit is forecasted to decline to about 447.4 M.

	2021	2022	2023	2024 (projected)
Gross Profit	980.8M	962.8M	457.1M	447.4M
Total Revenue	2.2B	2.2B	2.2B	2.3B

Gross Profit Total Revenue

Amedisys income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Ebitda	Cost Of Revenue	Total Operating Expenses	Total Other Income Expense Net	Net Income	Income Tax Expense	Income Before Tax	Extraordinary Items	Minority Interest	Net Income From Continuing Ops	Non Recurring	Non Operating Income Net Other	Discontinued Operations	Tax Provision	Interest Income	Net Interest Income	Reconciled Depreciation	Selling And Marketing Expenses
Depreciation And Amortization		0.2	0.55	0.61	0.85	0.6	0.26	0.25	0.37	0.36	0.61	0.18	0.37	0.15	0.32	-0.44	-0.02	0.26	-0.01	0.24	0.28	0.36	-0.38	-0.26	0.74	0.2
Interest Expense	0.2		0.78	0.73	0.13	0.69	0.4	0.36	0.37	0.88	-0.05	-0.53	0.07	0.39	0.15	-0.24	0.06	0.0	-0.13	-0.24	0.4	0.44	0.69	-0.94	0.64	-0.81
Selling General Administrative	0.55	0.78		0.97	0.62	0.88	0.58	0.59	0.64	0.94	0.24	-0.32	0.4	0.54	0.45	-0.66	0.07	0.23	-0.31	0.11	0.75	0.67	0.23	-0.73	0.75	-0.5
Total Revenue	0.61	0.73	0.97		0.72	0.96	0.5	0.47	0.53	0.93	0.4	-0.17	0.34	0.49	0.39	-0.69	0.14	0.16	-0.14	0.12	0.65	0.72	0.15	-0.7	0.75	-0.44
Gross Profit	0.85	0.13	0.62	0.72		0.72	0.25	0.24	0.34	0.42	0.76	0.28	0.36	0.22	0.34	-0.75	0.01	0.18	0.05	0.35	0.5	0.48	-0.52	-0.13	0.53	0.28
Other Operating Expenses	0.6	0.69	0.88	0.96	0.72		0.25	0.19	0.27	0.88	0.59	-0.16	0.08	0.25	0.13	-0.73	0.12	-0.09	0.14	0.04	0.47	0.59	0.17	-0.62	0.65	-0.4
Operating Income	0.26	0.4	0.58	0.5	0.25	0.25		0.95	0.95	0.53	-0.39	0.1	0.92	0.96	0.96	-0.04	0.33	0.89	-0.84	0.27	0.73	0.74	-0.02	-0.54	0.66	-0.3
Ebit	0.25	0.36	0.59	0.47	0.24	0.19	0.95		0.99	0.49	-0.44	-0.1	0.9	0.89	0.92	-0.1	0.12	0.85	-0.9	0.31	0.79	0.64	-0.02	-0.46	0.56	-0.25
Ebitda	0.37	0.37	0.64	0.53	0.34	0.27	0.95	0.99		0.51	-0.34	-0.07	0.91	0.87	0.93	-0.16	0.12	0.85	-0.86	0.33	0.79	0.66	-0.07	-0.47	0.64	-0.21
Cost Of Revenue	0.36	0.88	0.94	0.93	0.42	0.88	0.53	0.49	0.51		0.13	-0.37	0.25	0.52	0.33	-0.51	0.18	0.12	-0.2	-0.02	0.59	0.69	0.46	-0.84	0.71	-0.71
Total Operating Expenses	0.61	-0.05	0.24	0.4	0.76	0.59	-0.39	-0.44	-0.34	0.13		0.28	-0.28	-0.37	-0.31	-0.65	-0.06	-0.43	0.64	0.1	-0.04	0.04	-0.4	0.13	0.13	0.32
Total Other Income Expense Net	0.18	-0.53	-0.32	-0.17	0.28	-0.16	0.1	-0.1	-0.07	-0.37	0.28		0.32	0.15	0.3	0.1	0.47	0.35	0.06	0.32	-0.08	0.15	-0.73	0.38	0.0	0.57
Net Income	0.37	0.07	0.4	0.34	0.36	0.08	0.92	0.9	0.91	0.25	-0.28	0.32		0.85	0.99	-0.04	0.27	0.97	-0.83	0.42	0.68	0.61	-0.37	-0.23	0.54	0.07
Income Tax Expense	0.15	0.39	0.54	0.49	0.22	0.25	0.96	0.89	0.87	0.52	-0.37	0.15	0.85		0.91	-0.05	0.31	0.82	-0.76	0.33	0.73	0.81	-0.03	-0.51	0.57	-0.31
Income Before Tax	0.32	0.15	0.45	0.39	0.34	0.13	0.96	0.92	0.93	0.33	-0.31	0.3	0.99	0.91		-0.04	0.31	0.96	-0.84	0.41	0.71	0.68	-0.3	-0.31	0.57	-0.02
Extraordinary Items	-0.44	-0.24	-0.66	-0.69	-0.75	-0.73	-0.04	-0.1	-0.16	-0.51	-0.65	0.1	-0.04	-0.05	-0.04		0.06	0.2	-0.09	-0.18	-0.62	-0.25	0.16	0.08	-0.16	-0.03
Minority Interest	-0.02	0.06	0.07	0.14	0.01	0.12	0.33	0.12	0.12	0.18	-0.06	0.47	0.27	0.31	0.31	0.06		0.3	-0.21	0.12	0.07	0.37	-0.01	-0.23	0.28	-0.16
Net Income From Continuing Ops	0.26	0.0	0.23	0.16	0.18	-0.09	0.89	0.85	0.85	0.12	-0.43	0.35	0.97	0.82	0.96	0.2	0.3		-0.83	0.37	0.51	0.54	-0.33	-0.21	0.49	0.07
Non Recurring	-0.01	-0.13	-0.31	-0.14	0.05	0.14	-0.84	-0.9	-0.86	-0.2	0.64	0.06	-0.83	-0.76	-0.84	-0.09	-0.21	-0.83		-0.19	-0.64	-0.41	0.05	0.28	-0.31	0.15
Non Operating Income Net Other	0.24	-0.24	0.11	0.12	0.35	0.04	0.27	0.31	0.33	-0.02	0.1	0.32	0.42	0.33	0.41	-0.18	0.12	0.37	-0.19		0.28	0.37	-0.37	0.25	0.14	0.25
Discontinued Operations	0.28	0.4	0.75	0.65	0.5	0.47	0.73	0.79	0.79	0.59	-0.04	-0.08	0.68	0.73	0.71	-0.62	0.07	0.51	-0.64	0.28		0.55	-0.08	-0.35	0.39	-0.18
Tax Provision	0.36	0.44	0.67	0.72	0.48	0.59	0.74	0.64	0.66	0.69	0.04	0.15	0.61	0.81	0.68	-0.25	0.37	0.54	-0.41	0.37	0.55		-0.06	-0.57	0.68	-0.3
Interest Income	-0.38	0.69	0.23	0.15	-0.52	0.17	-0.02	-0.02	-0.07	0.46	-0.4	-0.73	-0.37	-0.03	-0.3	0.16	-0.01	-0.33	0.05	-0.37	-0.08	-0.06		-0.57	0.1	-0.86
Net Interest Income	-0.26	-0.94	-0.73	-0.7	-0.13	-0.62	-0.54	-0.46	-0.47	-0.84	0.13	0.38	-0.23	-0.51	-0.31	0.08	-0.23	-0.21	0.28	0.25	-0.35	-0.57	-0.57		-0.76	0.74
Reconciled Depreciation	0.74	0.64	0.75	0.75	0.53	0.65	0.66	0.56	0.64	0.71	0.13	0.0	0.54	0.57	0.57	-0.16	0.28	0.49	-0.31	0.14	0.39	0.68	0.1	-0.76		-0.34
Selling And Marketing Expenses	0.2	-0.81	-0.5	-0.44	0.28	-0.4	-0.3	-0.25	-0.21	-0.71	0.32	0.57	0.07	-0.31	-0.02	-0.03	-0.16	0.07	0.15	0.25	-0.18	-0.3	-0.86	0.74	-0.34

Click cells to compare fundamentals

Amedisys Account Relationship Matchups

Amedisys income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Interest Expense	14.5M	11.0M	9.5M	22.2M	31.3M	32.8M
Total Revenue	2.0B	2.1B	2.2B	2.2B	2.2B	2.3B
Gross Profit	805.3M	886.2M	980.8M	962.8M	457.1M	447.4M
Operating Income	177.5M	219.3M	251.9M	180.8M	193.1M	202.7M
Ebit	177.5M	219.3M	251.9M	180.8M	193.1M	202.7M
Ebitda	240.7M	294.0M	329.9M	256.4M	216.9M	227.8M
Cost Of Revenue	1.2B	1.2B	1.2B	1.3B	1.8B	1.9B
Net Income	126.8M	183.6M	209.1M	118.6M	(9.7M)	(9.3M)
Income Tax Expense	42.5M	25.6M	70.1M	42.5M	50.6M	53.1M
Income Before Tax	170.4M	210.8M	280.2M	160.2M	39.6M	45.7M
Minority Interest	1.1M	1.6M	1.1M	(910K)	1.1M	1.1M
Tax Provision	42.5M	25.6M	70.1M	42.5M	50.2M	42.3M
Interest Income	78K	292K	49K	178K	2.5M	2.6M
Net Interest Income	(14.4M)	(10.7M)	(9.5M)	(22.1M)	(26.3M)	(25.0M)

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Amedisys in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Amedisys' short interest history, or implied volatility extrapolated from Amedisys options trading.

Pair Trading with Amedisys

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Amedisys position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Amedisys will appreciate offsetting losses from the drop in the long position's value.

Moving together with Amedisys Stock

0.71

JNJ

Johnson Johnson Aggressive Push

Pair Corr

Moving against Amedisys Stock

0.84	XOM	Exxon Mobil Corp Earnings Call Tomorrow	Pair Corr
0.83	CAT	Caterpillar Earnings Call Today	Pair Corr
0.8	AXP	American Express Financial Report 19th of July 2024	Pair Corr
0.78	BAC	Bank of America Sell-off Trend	Pair Corr
0.76	CVX	Chevron Corp Earnings Call Tomorrow	Pair Corr

The ability to find closely correlated positions to Amedisys could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Amedisys when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Amedisys - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Amedisys to buy it.

The correlation of Amedisys is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Amedisys moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Amedisys moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Amedisys can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Amedisys is a strong investment it is important to analyze Amedisys' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Amedisys' future performance. For an informed investment choice regarding Amedisys Stock, refer to the following important reports:

How To Invest In Amedisys

Details

Is Amedisys Stock a good investment?

Details

What is Amedisys' Net Worth?

Details

Largest Health Care Providers & Services Companies

View

Largest Health Care Equipment & Services Companies

View

Check out Amedisys Valuation and Amedisys Correlation analysis.

For information on how to trade Amedisys Stock refer to our How to Trade Amedisys Stock guide.

Note that the Amedisys information on this page should be used as a complementary analysis to other Amedisys' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.

Complementary Tools for Amedisys Stock analysis

When running Amedisys' price analysis, check to measure Amedisys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amedisys is operating at the current time. Most of Amedisys' value examination focuses on studying past and present price action to predict the probability of Amedisys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amedisys' price. Additionally, you may evaluate how the addition of Amedisys to your portfolios can decrease your overall portfolio volatility.

	Economic Indicators Top statistical indicators that provide insights into how an economy is performing
	Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
	Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
	FinTech Suite Use AI to screen and filter profitable investment opportunities
	Transaction History View history of all your transactions and understand their impact on performance
	Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets
	USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA
	Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios.
	Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios
	ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
	Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk
	Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments
	My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like

Is Amedisys' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amedisys. If investors know Amedisys will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amedisys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.40)

Earnings Share

(0.30)

Revenue Per Share

68.603

Quarterly Revenue Growth

0.016

Return On Assets

0.0598

The market value of Amedisys is measured differently than its book value, which is the value of Amedisys that is recorded on the company's balance sheet. Investors also form their own opinion of Amedisys' value that differs from its market value or its book value, called intrinsic value, which is Amedisys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amedisys' market value can be influenced by many factors that don't directly affect Amedisys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Amedisys' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amedisys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amedisys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Amedisys Income Statement Research

Amedisys income statement Correlations

Amedisys Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Amedisys income statement Accounts

Pair Trading with Amedisys

Moving together with Amedisys Stock

Moving against Amedisys Stock

Complementary Tools for Amedisys Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ebitda	+ 0.99	Ebit
Income Before Tax	+ 0.99	Net Income
Total Revenue	+ 0.97	Selling General Administrative
Net Income From Continuing Ops	+ 0.97	Net Income
Other Operating Expenses	+ 0.96	Total Revenue
Income Tax Expense	+ 0.96	Operating Income

Net Interest Income	- 0.94	Interest Expense
Non Recurring	- 0.9	Ebit
Selling And Marketing Expenses	- 0.86	Interest Income
Non Recurring	- 0.86	Ebitda
Non Recurring	- 0.84	Income Before Tax
Net Interest Income	- 0.84	Cost Of Revenue